In Antifolate Drugs in Cancer Therapy Ann Jackman and a panel of highly regarded researchers
comprehensively review the current status of novel antifolates an important class of
anticancer drugs. The distinguished contributors discuss the preclinical and clinical
pharmacology of methotrexate other dihydrofolate reductase inhibitors 5-fluorouracil and the
new generation of antifolates-the thymidylate synthase and glycinamide ribonucleotide
formyltransferase inhibitors. In addition they review in depth the modulation of antifolate
drugs folate and antifolate transport mechanisms polyglutamation resistance and drug
combinations as well as pharmacogenomics pharmacodynamics regulation of gene expression and
mechanisms of cell death. The wide and progressive scope of Antifolate Drugs in Cancer Therapy
provides entré to exciting new avenues for future research and constitutes a new standard
reference for all basic scientists and clinicians engaged in cancer therapeutics.
